Paid Clinical Trials Santa Ana

Discover 3,370 paid clinical trials in Santa Ana, California. Search by condition or phase to find a research study near you that matches your needs across various therapeutic areas.

Filter

Filter results

Results: 3,370

Study of Patients With Body Image Issues Treated With 2 Different Behavioral Interventions

Recruiting

PHASE2

Sponsor:

Westwood Institute for Anxiety Disorders, Inc

Location:

Los Angeles

Code:

NCT01316627

Conditions

Body Dysmorphic Disorders

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Crooked Mirror Externalization Therapy

Mirror Retraining Method

Single-Blind Study of STAT-205 in Mild COVID-19

Recruiting

PHASE1

Sponsor:

Cytocom, Inc.

Location:

Loma Linda, Pompano Beach

Code:

NCT04708327

Conditions

COVID-19

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

STAT-205

Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant

Recruiting

PHASE1

Sponsor:

City of Hope Medical Center

Location:

Duarte

Code:

NCT06498973

Conditions

Acute Myeloid Leukemia

Myelodysplastic Syndrome

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Azacitidine

Biospecimen Collection

Bone Marrow Aspiration

Bone Marrow Biopsy

Questionnaire Administration

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Recruiting

PHASE2

Sponsor:

Allogene Therapeutics

Location:

Duarte, Los Angeles, Berkeley, Sacramentoshow 27 more

Code:

NCT06500273

Conditions

Large B-cell Lymphoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

cemacabtagene ansegedleucel

ALLO-647

Fludarabine

Cyclophosphamide

Foresight CLARITY™ IUO MRD test, powered by PhasED-Seq™

A Study of BG-C477 in Participants With Advanced Solid Tumors

Recruiting

PHASE1

Sponsor:

BeiGene

Location:

Duarte, Westwood, Houston, New Haven

Code:

NCT06596473

Conditions

Advanced Solid Tumors

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

BG-C477

Chemotherapy

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis

Recruiting

PHASE3

Sponsor:

Sanofi

Location:

Irvine, Laguna Hills, West Hollywood, Carlsbadshow 78 more

Code:

NCT06141473

Conditions

Multiple Sclerosis

Eligibility Criteria

Sex: All

Age: 18 - 55

Healthy Volunteers: Not accepted

Interventions

Frexalimab

Teriflunomide

Placebo infusion

Placebo tablet

MRI contrast-enhancing agents

Study of Sacituzumab Govitecan in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

Recruiting

PHASE2

Sponsor:

Gilead Sciences

Location:

Los Angeles, San Francisco, Tucson, Salt Lake Cityshow 31 more

Code:

NCT03547973

Conditions

Metastatic Urothelial Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Sacituzumab Govitecan-hziy

Pembrolizumab

Cisplatin

Avelumab

Zimberelimab

A Study of Amivantamab in People with Esophagogastric Cancer

Recruiting

PHASE2

Sponsor:

Memorial Sloan Kettering Cancer Center

Location:

Irvine, Basking Ridge, Middletown, Montvaleshow 5 more

Code:

NCT05117931

Conditions

Esophagogastric Cancer

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Amivantamab

Boosting Language Outcomes of Minimally Verbal Children With ASD (BLOOM)

Recruiting

Sponsor:

UCLA

Location:

Los Angeles

Code:

NCT04218331

Conditions

Autism Spectrum Disorder

Eligibility Criteria

Sex: All

Age: 48 - 66

Healthy Volunteers: Not accepted

Interventions

JASPER

PROMPT

Study of XB010 in Subjects With Solid Tumors

Recruiting

PHASE1

Sponsor:

Exelixis

Location:

Duarte, Oklahoma City, Austin, Saint Louisshow 2 more

Code:

NCT06545331

Conditions

Locally Advanced or Metastatic Solid Tumors

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

XB010

Pembrolizumab